Compare Davita Inc (DVA) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Expensify Inc — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Expensify Inc trades at $2.27 (market cap $224.32M). The key difference: Davita Inc is far larger — about 52.2× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | EXFY | |
|---|---|---|
Market Cap | $11.72B | $224.32M |
Sector | Health | Technology |
52-Week High | $240.96 | $2.69 |
52-Week Low | $103.87 | $0.75 |
Enterprise Value | $24.44B | $163.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Expensify (EXFY) trades at $2.69, up 35.86% in 24 hours, with a bullish technical signal from moving averages but overbought RSI levels. The company reported Q2 2026 revenue of $33.9 million, beating EPS estimates, and raised free cash flow guidance. Despite negative net margins, cash flow from operations improved to $20.09 million in 2025, and the balance sheet shows $48.77 million in cash with low debt.
The outlook is cautiously optimistic due to earnings beats and AI-driven growth initiatives, but high P/E of 258.82 and persistent losses pose valuation risks. Analyst consensus is split between Buy and Hold, reflecting uncertainty over profitability sustainability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
